Drug Profile
Ondansetron oral spray - Arovella Therapeutics
Alternative Names: Ondansetron lingual spray; Ondansetron OS; Ondansetron succinate oro-mucosal spray - Arovella Therapeutics; SUD-002; SUDA-002; Zensana; ZondaMistLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator NovaDel Pharma
- Developer Arovella Therapeutics
- Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting; Radiotherapy-induced nausea and vomiting
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for clinical-Phase-Unknown development in Chemotherapy-induced-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Postoperative-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)